New table highlighting results in IMDC favorable risk RCC across IO-based doublets and nivo/pembro monotx trials. Major caveats about small subsets and differing follow-up, but interesting observations emerge. Thanks to Toni Choueiri, MD and Mike Atkins for help assembling data.

Adjuvant atezolizumab does not show benefit over placebo in high risk renal cancer for DFS/OS. No benefit even in M1 subgroup? This contrasts the pembro. Immotion150 showed atezo had a RR ~25% in advanced disease. PD-L1 therapy maybe less good than PD1 therapy here. #ESMO22

Excited to kick-off #CKCF22 in-person, Oct 13-15! Thrilled to have 🇨🇦 #RCC collaborators elbow-to-elbow, and of course welcome our international speakers — Rana McKay, MD, FASCO (UC San Diego Health) & @Merregan (Dana-Farber) Canadian Urological Association Canadian Kidney Cancer information system (CKCis) Hotel X Toronto @lukelavallee

On behalf of the meeting chair Anil Kapoor, MD, FRCSC and scientific program co-chairs Aly-Khan Lalani and Luke Lavallee welcome to #ckcf22.

Day 2 of #CKFC22, AM sessions focusing on: - approaches to localized #RCC, renal masses - predicting recurrence post surgery Rod Breau - tumour board - prognostic factors in IO era @Merregan - the great debate! adjuvant IO Rana McKay, MD, FASCO vs Anil Kapoor, MD, FRCSC

#CKCF22 @Merregan (Dana-Farber) asks how we could reassess #RCC prognostic factors in current IO era… - time-varying approach, - possibility of additional factors, - goals for future models: is “simple” always best? Canadian Urological Association Jeffrey Graham Simon Tanguay

#CKCF22: Gloves are off for fun and informative debate on adjuvant IO in #RCC - captures contemporary talking points in this evolving space! Yay Rana McKay, MD, FASCO Nay Anil Kapoor, MD, FRCSC Canadian Urological Association Simon Tanguay Jeffrey Graham @Merregan @lukelavallee

1 Meeting #CKCF2022 4 teams...some injuries later! We have a winning team w/ @lukelavallee Kristen McAlpine Rod Breau . Thank you participants! Are we having bingo next year Anil Kapoor, MD, FRCSC ? Aly-Khan Lalani Shaan Dudani Bimal Bhindi Dominick Bossé, MD MPH Tiffany Pizioli Simon Tanguay Naveen Basappa, MD

McDavid: 498 career assists Matthews: 497 career points That’s all what needs to be said

The publication of the IMDC prognostic groups in 2009 raises the question of whether they are still relevant in the era of "contemporary" treatments. Answer: YES! Valid thru! European Urology OncoAlert Daniel Heng Toni Choueiri, MD Rana McKay, MD, FASCO Aly-Khan Lalani ASCO doi.org/10.1016/j.euru…

Accelerated approval for EV+pembrolizumab- ORR Cohorts A &K of 68%! Potentially transformative for advanced urothelial ca- all eyes now on EV-302. Kudos to an amazing study team! Memorial Sloan Kettering Cancer Center Matt Milowsky Christopher Hoimes Daniel Petrylak Thomas Flaig bit.ly/3zvmvnI

Tragic case of fatal #5FU toxicity - grateful that Dr. Anil Kapoor’s family has taken this issue public. CBC News: The National Hopefully will push resources for routine DPYD screening 🇨🇦 ➡️BC Cancer adopted DPYD testing in BC last year🙏 ➡️ we need to learn more about variants in

Poster #389: Management, Outcomes, and Predictors of Recurrence and Survival in Localized Chromophobe RCC. #CKCis #GU24 #RWE #kidneycancer #chromophobeRCC #chromophobe Naveen Basappa, MD Rod Breau Ricardo Rendon Simon Tanguay Tony Finelli Rahul Bansal Bimal Bhindi

Poster #393: Ipi/Nivo compared to Axi/Pembro in mRCC. #CKCis #RWE #registry #GU24 #CanadianData Hyejee Ohm Naveen Basappa, MD Rod Breau Jeffrey Graham Daniel Heng Tony Finelli Simon Tanguay Aly-Khan Lalani Bimal Bhindi

Poster #416: Impact and Timing of Immunotherapy and CN on Outcomes in mRCC. #CKCis #GU24 #RWE #Canadian #kidneycancer Larry (Changsu) Park Naveen Basappa, MD Rod Breau Daniel Heng Ramy Saleh, MD, MSc Simon Tanguay Jeffrey Graham Aly-Khan Lalani Tony Finelli Dominick Bossé, MD MPH

Poster #366: Real-world practice patterns, treatment-related toxicity, and survival outcomes in older pts with mRCC. #CKCis #GU24 #RWE #registry #kidneycancer Maryam Soleimani MD Simon Tanguay Aly-Khan Lalani Daniel Heng Naveen Basappa, MD Rod Breau Jeffrey Graham

Poster #367: Real-world efficacy and toxicity of Ipi and Nivo for first line treatment of mRCC. #ckcis #kidneycancer #GU24 Christina Canil Naveen Basappa, MD Rod Breau Simon Tanguay @DSoulieresMD Aly-Khan Lalani Jeffrey Graham Tony Finelli Bimal Bhindi

Another great #CKCis OC meeting at #CKCF24. Thank you to all of our sites for their continued hard effort and to our supporters! #kidneycancer #registry #Canadian Naveen Basappa, MD Rod Breau Simon Tanguay Rahul Bansal Robert Bick Tony Finelli Jeffrey Graham

A touching tribute to the imitable Dr. Anil Kapoor at #CKCF24 . A remarkable mentor, urologist and one of the kindest, and most witty people in any room. He will be dearly missed and has forever left a legacy in the world of #RCC . Canadian Urological Association

edmontonjournal.com/opinion/column…